Kornitzer Capital Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q3
Sell
-106,899
Closed -$3.54M 507
2019
Q2
$3.54M Sell
106,899
-525
-0.5% -$18K 0.06% 282
2019
Q1
$3.76M Sell
107,424
-85
-0.1% -$3.16K 0.07% 268
2018
Q4
$3.57M Sell
107,509
-42,276
-28% -$1.82M 0.07% 262
2018
Q3
$7.54M Buy
149,785
+425
+0.3% +$21K 0.12% 212
2018
Q2
$8.94M Sell
149,360
-77,620
-34% -$4.02M 0.15% 188
2018
Q1
$10.4M Sell
226,980
-20,625
-8% -$861K 0.18% 163
2017
Q4
$9.87M Sell
247,605
-18,660
-7% -$737K 0.17% 175
2017
Q3
$10.7M Sell
266,265
-70,500
-21% -$3.05M 0.19% 167
2017
Q2
$14.5M Sell
336,765
-65,670
-16% -$2.34M 0.25% 125
2017
Q1
$12.6M Hold
402,435
0.22% 139
2016
Q4
$10.2M Sell
402,435
-356,270
-47% -$7.96M 0.19% 172
2016
Q3
$18.8M Sell
758,705
-78,420
-9% -$1.77M 0.34% 98
2016
Q2
$17.1M Buy
837,125
+56,410
+7% +$1M 0.31% 116
2016
Q1
$11.9M Sell
780,715
-464,455
-37% -$6.06M 0.2% 168
2015
Q4
$16.7M Buy
1,245,170
+412,280
+49% +$6.38M 0.27% 137
2015
Q3
$11.7M Buy
+832,890
New +$15.5M 0.19% 173

Other funds holding SUPN

Kornitzer Capital Management's SUPN Position: Q3 2019 in Review

Kornitzer Capital Management sold out of Supernus Pharmaceuticals (SUPN) in Q3 2019, closing a stake of 106,899 shares — an estimated $3.54M sold.

Kornitzer Capital Management first reported a position in SUPN in Q3 2015 and held it in 16 quarters. The position peaked at $18.8M in Q3 2016. 243 funds tracked by Wall St. Rank hold SUPN as of Q3 2019.

  • Kornitzer Capital Management reported no remaining Supernus Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Kornitzer Capital Management sold 106,899 Supernus Pharmaceuticals shares in Q3 2019, an estimated $3.54M.
  • Kornitzer Capital Management first reported a position in Supernus Pharmaceuticals in Q3 2015 and held it in 16 quarters.
  • Kornitzer Capital Management's Supernus Pharmaceuticals position peaked at $18.8M in Q3 2016.
  • 243 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2019.

Based on Kornitzer Capital Management's 13F filing for Q3 2019, filed 4 Nov 2019.